Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus.

Arab JP, Claro JC, Arancibia JP, Contreras J, Gómez F, Muñoz C, Nazal L, Roessler E, Wolff R, Arrese M, Benítez C.

World J Hepatol. 2016 Sep 8;8(25):1075-86. doi: 10.4254/wjh.v8.i25.1075.

2.

Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - Revised.

Executive Committee of the German Medical Association on the Recommendation of the Scientific Advisory Board..

Transfus Med Hemother. 2016 May;43(3):223-32. doi: 10.1159/000446043. Epub 2016 May 3.

3.

Population Based Trends in the Incidence of Hospital Admission for the Diagnosis of Hepatorenal Syndrome: 1998-2011.

Suneja M, Tang F, Cavanaugh JE, Polgreen LA, Polgreen PM.

Int J Nephrol. 2016;2016:8419719. doi: 10.1155/2016/8419719. Epub 2016 Apr 6.

4.

Hyponatremia and Hepatorenal Syndrome.

Mohanty A, Garcia-Tsao G.

Gastroenterol Hepatol (N Y). 2015 Apr;11(4):220-9.

5.

AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis.

Caraceni P, Angeli P, Prati D, Bernardi M; Italian Association for the Study of the Liver (AISF)., Liumbruno GM, Bennardello F, Piccoli P, Velati C; Italian Society of Transfusion Medicine and Immunohaematology (SIMTI)..

Blood Transfus. 2016 Jan;14(1):8-22. doi: 10.2450/2016.0294-15.

6.

Terlipressin and albumin for type 1 hepatorenal syndrome: does bacterial infection affect the response?

Altun R, Korkmaz M, Yıldırım E, Öcal S, Akbaş E, Selçuk H.

Springerplus. 2015 Dec 23;4:806. doi: 10.1186/s40064-015-1625-z. eCollection 2015.

7.

Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis.

Salerno F, Navickis RJ, Wilkes MM.

BMC Gastroenterol. 2015 Nov 25;15:167. doi: 10.1186/s12876-015-0389-9.

8.

Creatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-Analysis.

Belcher JM, Coca SG, Parikh CR.

PLoS One. 2015 Aug 21;10(8):e0135625. doi: 10.1371/journal.pone.0135625. eCollection 2015. Review.

9.

Treatment and management of ascites and hepatorenal syndrome: an update.

Lenz K, Buder R, Kapun L, Voglmayr M.

Therap Adv Gastroenterol. 2015 Mar;8(2):83-100. doi: 10.1177/1756283X14564673. Review.

10.

Albumin administration in the acutely ill: what is new and where next?

Vincent JL, Russell JA, Jacob M, Martin G, Guidet B, Wernerman J, Ferrer R, McCluskey SA, Gattinoni L.

Crit Care. 2014 Jul 16;18(4):231. doi: 10.1186/cc13991. Review. Erratum in: Crit Care. 2014;18(6):630. Roca, Ricard Ferrer [corrected to Ferrer, Ricard].

11.

Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study.

Licata A, Maida M, Bonaccorso A, Macaluso FS, Cappello M, Craxì A, Almasio PL.

World J Hepatol. 2013 Dec 27;5(12):685-91. doi: 10.4254/wjh.v5.i12.685.

12.

Cirrhotic ascites review: Pathophysiology, diagnosis and management.

Moore CM, Van Thiel DH.

World J Hepatol. 2013 May 27;5(5):251-63. doi: 10.4254/wjh.v5.i5.251.

13.

Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: a meta-analysis.

Hiremath SB, Srinivas LD.

Indian J Pharmacol. 2013 Jan-Feb;45(1):54-60. doi: 10.4103/0253-7613.106436.

14.

Improving survival in decompensated cirrhosis.

Mukerji AN, Patel V, Jain A.

Int J Hepatol. 2012;2012:318627. doi: 10.1155/2012/318627. Epub 2012 Jul 2.

15.

Revision and update on clinical practice guideline for liver cirrhosis.

Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, Kim YS, Lee JW, Kim DJ, Cho SW, Hwang SG, Sohn JH, Kim MY, Kim YB, Kim JG, Cho YK, Choi MS, Kim HJ, Lee HW, Kim SU, Kim JK, Choi JY, Jun DW, Tak WY, Lee BS, Jang BK, Chung WJ, Kim HS, Jang JY, Jeong SW, Kim SG, Kwon OS, Jung YK, Choe WH, Lee JS, Kim IH, Shim JJ, Cheon GJ, Bae SH, Seo YS, Choi DH, Jang SJ; Korean Association for the Study of the Liver..

Korean J Hepatol. 2012 Mar;18(1):1-21. doi: 10.3350/kjhep.2012.18.1.1. Epub 2012 Mar 22. No abstract available.

16.

Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.

Nadim MK, Kellum JA, Davenport A, Wong F, Davis C, Pannu N, Tolwani A, Bellomo R, Genyk YS; ADQI Workgroup..

Crit Care. 2012 Feb 9;16(1):R23. doi: 10.1186/cc11188. Review.

17.

Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials.

Velez JC, Nietert PJ.

Am J Kidney Dis. 2011 Dec;58(6):928-38. doi: 10.1053/j.ajkd.2011.07.017. Epub 2011 Sep 29.

18.

Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.

Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V, Sigal S, Bexon AS, Teuber P; Terlipressin Study Group..

Liver Transpl. 2011 Nov;17(11):1328-32. doi: 10.1002/lt.22395.

19.

Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics.

Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, Teuber P; Terlipressin Study Group..

J Hepatol. 2011 Aug;55(2):315-21. doi: 10.1016/j.jhep.2010.11.020. Epub 2010 Dec 15.

20.

Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists.

Magan AA, Khalil AA, Ahmed MH.

World J Gastroenterol. 2010 Nov 7;16(41):5139-47. Review.

Supplemental Content

Support Center